We value your privacy
We use cookies to understand how our site is used so we can improve it. Necessary cookies are always on. You can accept all, reject all, or choose what to allow. Learn more
CLASSYS sells skin-tightening devices to clinics at razor-thin economics, then earns for years on the single-use cartridges every treatment burns. Revenue tripled in five years while operating margin never left 50% — the exact trick the Western rivals who sold 'just the machine' couldn't manage. Two of them went bankrupt proving it.
In 1901 King Camp Gillette had a strange idea: give the razor away, and make your money forever on the blades. The handle was a one-time sale; the blades were a habit. A century later the most profitable version of that idea is not in a bathroom cabinet — it is on the treatment beds of dermatology clinics, and the company that has perfected it is one most people outside Korea have never heard of.
Its name is CLASSYS. From Seoul, it makes the machines that tighten and lift skin without surgery — the focused-ultrasound and radiofrequency devices clinics market under names like Shurink and Ultraformer. It places those machines in clinics at deliberately keen prices, and then earns, year after year, on the single-use cartridges that every treatment consumes. It is Gillette, for faces. And on that simple structure it has built a business with the kind of economics most hardware companies can only dream about.
Here is how the loop works. A focused-ultrasound device fires energy beneath the skin to stimulate lifting and tightening. Each session burns through a cartridge metered by the number of 'shots' it delivers; when the cartridge is spent, the clinic has to buy another. CLASSYS even seeds new clinics with free cartridge vouchers to get the habit started — a giveaway that quietly pre-sells the annuity. The machine is bought once. The cartridge is bought forever.
By 2025 that recurring stream — the blade — had grown to roughly 46% of the company's revenue, and it was compounding nearly as fast as the device line itself. That is the number a careful investor circles. It means almost half the business is sticky, high-margin re-orders that arrive whether or not a clinic is in the mood to buy a new machine this quarter.
One email, once a month. Curated deep dives, regulatory updates, and expert perspectives from Nathan Research Group.
2025 operating margin on ₩336.8bn (~US$245m) of revenue
50.7%
For a company that 'makes machines,' a ~50% operating margin is closer to a software firm's than a hardware maker's.
Between 2021 and 2025 CLASSYS roughly tripled its revenue. Companies that grow that fast almost always pay for it in margin — they cut price to win share, or the mix tilts toward lower-value products. CLASSYS did neither. Its operating margin stayed pinned in a narrow band around 50% for five straight years, through a more-than-threefold expansion in sales. Growth and fat margins are supposed to be a trade-off. Here they weren't.
The reason is the annuity. Every new machine placed in a clinic anywhere in the world quietly enlarges the base of cartridges that must be re-ordered for years afterward. The more razors out in the field, the more blades sell — at the same high margin — so the incremental dollar of revenue increasingly comes from consumables rather than from one-off hardware. That is why the company can grow like a device maker and earn like an annuity. The installed base, now north of 35,000 devices, is the asset; the cartridge re-order is the realised return.
“A device maker sells you a machine once and then hopes you buy the next one. A blade business sells you the machine once and then gets paid every time you use it. Only one of those is worth a fifty-per-cent margin.”
— Nathan Research Group, Medical Aesthetics Series N°08
The cleanest way to see why the blade matters is to look at the companies that didn't have one. InMode, the US-Israeli device maker, had the brand, the technology and a fortress balance sheet — but its mix was roughly 78% machine and only 22% consumable. When American clinics stopped buying equipment through 2024 and 2025, there was almost no recurring revenue to cushion the fall. Sales slid from a peak near US$492m to about US$370m, and operating margin roughly halved.
Cutera went further down the same road. It bet the company on a single new acne device, funded the wager with debt, and when growth stalled its margins collapsed and it filed for Chapter 11 bankruptcy in March 2025. The lesson both companies teach is the one CLASSYS is built on: 'aesthetic device maker' is not, by itself, a quality business. The quality lives in the blade and the balance sheet.
Those are the three things the failures lacked — and the three things CLASSYS has. It is, in effect, the inverse of Cutera on every axis that broke Cutera.
Three currents are pushing demand toward exactly what these devices do. The first is the weight-loss drug wave. As millions lose weight quickly on GLP-1 medications, many are left with the loose, deflated skin the tabloids call 'Ozempic face' — and a McKinsey survey found that around 63% of GLP-1 users seeking aesthetic treatment had never been aesthetic customers before. That is a brand-new pool of demand walking straight into the skin-tightening category.
The second is the shift from surgery to 'tweakments' — lower-cost, no-downtime procedures you can have on a lunch break and post about the same afternoon. It is pulling in younger clients and, increasingly, first-time men. The third is the Korea effect. Korea is the world's R&D lab for aesthetics: energy-based devices already account for roughly 63% of its domestic aesthetic market, and foreign medical-tourism patients hit a record of around two million in 2025. The country both writes the playbook and exports it — CLASSYS already sells in some 80 countries, with two-thirds of its revenue earned abroad.
There is one wrinkle that turns this from a tidy business story into an interesting situation. The jewel is not founder-run. Bain Capital took control of CLASSYS in 2022 and now badges it as its flagship Korean 'value-up' success — and a private-equity owner is, by definition, a temporary one. Bain has begun trimming its stake, and a full sale has been floated and, by mid-2026, reportedly paused on price. None of that changes how the business works. It simply means a great machine sits inside a sponsor's timeline — and for any buyer the question was never whether the business is good. It is at what price the owner will let go.
The lesson travels well beyond one Korean company. In any business that looks like a 'device' sale — aesthetics, dialysis, coffee pods, printers — the value usually hides in the consumable, not in the box. The right question is rarely 'how many machines did you sell?' It is 'how large is the installed base, and how reliably does it re-order?' Answer that, and you have most of what you need to know about whether the margins are real or borrowed.
For CLASSYS specifically, the one thing worth watching is whether the blade stays proprietary as cheaper copies appear and the field crowds. The annuity is the moat; the durability of that annuity is the whole investment question. But the structure itself — give away the razor, own the blade — is as sound today as it was when Gillette first drew it up. Nathan Research Group has specialised in the Korean economy since 2013; the businesses that look simplest from the outside are often where the most durable economics are hiding.